Taiwan as a Quality-First China+1 for Health Devices

Diversification has moved past “whether”

For supply-chain teams sourcing medical and health devices, the question is no longer whether to add a second production base outside China. It is which one, and on what criteria.

The direction of travel is visible across the sourcing data. In QIMA’s 2025 Global Sourcing Survey, roughly two-thirds of companies planned to maintain or expand business with China in 2025, while the pivot to alternative hubs like Vietnam, India, and Mexico continued at a slower pace and half of businesses boosted local and regional sourcing in 2024. Diversification, in other words, is additive rather than a wholesale exit. Even inside China, a DP World Global Trade Observatory survey of 292 supply-chain and logistics executives found supplier diversification was the leading resilience strategy, with 58% planning to increase their number of suppliers, ahead of near-shoring (38%) and friend-shoring (36%).

Most published guidance stops there and points buyers toward the lowest-labor-cost destination in Southeast Asia. That answer works for high-volume, low-complexity goods. It is a poor default for regulated devices, where the cost of a field failure, a documentation gap, or a design leak dwarfs the line-item saving on assembly labor. For that category, the more useful exercise is to evaluate a candidate country on the dimensions that actually govern device outcomes.

A framework beyond unit cost

Unit cost is the easiest number to compare and the least predictive of total landed risk for a medical or health device. Four other dimensions carry more weight over a product’s life.

Quality-system maturity. Not whether a factory holds a certificate, but how deeply regulated-device disciplines—design controls, process validation, traceability, third-party testing—are embedded across the local supplier base. A dense cluster of firms already working to those standards is easier and faster to qualify than an isolated factory learning them for your program. It also matters downstream: when a component supplier, a tooling shop, and a test house in the same region all speak the same quality vocabulary, a corrective action closes in days rather than in a chain of translated emails. Certificates tell you a factory passed an audit once; cluster density tells you the discipline is normal, not exceptional.

IP protection and legal recourse. For a device that embeds proprietary mechanical design, firmware, and electronics, the enforceability of patents and trade secrets is a design input, not a legal footnote. What matters is whether a jurisdiction has a functioning court, defined remedies, and a track record of applying them. The practical test is what happens after a dispute: does a rights holder have a venue that understands technical evidence, and remedies with teeth—injunctions, damages, seizure at the border? A production base where those answers are clear lets you place more of your IP with the manufacturer, which in turn lets the manufacturer do more of the engineering. Where they are unclear, brands ring-fence their design, and the relationship never gets past build-to-print.

Engineering and tooling capability. Can the base do more than build to print? Devices with sensors, batteries, power management, and custom modules need local mechanical and electronics engineering, in-house tooling, and PCBA competence—or every change order becomes a transpacific delay. The value of co-located engineering shows up most in the messy middle of a program: a tolerance that has to open up after first articles, a battery that fails a drop test, a module that needs a revision two weeks before a trade show. If the people who can make those calls sit next to the line, the loop is hours. If they sit an ocean away, it is weeks, and each week compounds.

Communication and proximity to end markets. Regulated products live and die on documentation and change control. Time-zone overlap with your team, engineers who answer questions directly, and short physical distance to your primary markets reduce the round-trip cost of every clarification. Distance is not only geographic. A shared working language, familiarity with the documentation conventions your target market expects, and a culture of answering the actual question asked all shorten the path from a design intent in your office to a validated build on the floor.

Rank a candidate on those four before ranking it on price, and the shortlist for health devices looks different from the shortlist for commodity goods.

Where Taiwan sits

Taiwan is rarely the first name in a China+1 discussion, which is precisely why it is under-evaluated on these criteria.

A contract-manufacturing base built for devices. According to the U.S. International Trade Administration, most Taiwan medical device manufacturers produce mid-to-low-end equipment and provide contract manufacturing for multinationals, with globally competitive positions in categories such as wheelchairs, medical furniture, and basic surgical instruments, and expansion into orthopedic and implantable products, contact lenses, and monitoring devices like blood-pressure and glucose monitors. The relevant point for a buyer is structural: the island’s device sector is organized around building to other companies’ specifications and standards. That is the exact muscle a China+1 program needs, and it sits next to one of the world’s deepest electronics and PCBA ecosystems—directly relevant to health devices that are, increasingly, electronics products with a medical enclosure.

An IP regime with defined remedies. Taiwan protects three patent types—invention (20-year term), utility model (10-year term), and design (15-year term)—administered by the Taiwan Intellectual Property Office under the Ministry of Economic Affairs. Trademarks run on a first-to-file system, and trade-secret protection covers information that is non-public, economically valuable, and kept under reasonable confidentiality measures. Disputes are heard by a dedicated Intellectual Property and Commercial Court where technical examination officers sit alongside judges, and enforcement tools include customs seizures, civil injunctions and damages, and criminal prosecution. For a brand whose device is its IP, a jurisdiction with a specialized court and defined remedies is a materially different proposition from one without.

Engineering supply and communication. Taiwan’s manufacturing culture pairs contract-manufacturing depth with local design and tooling capacity, and its firms have long served U.S., European, and Japanese customers—the primary export markets for its device makers. Practically, that means English- and Japanese-facing communication is normal, and the working relationship can run engineer-to-engineer rather than through a sales layer.

There is also a category-fit argument that the cost comparison misses. Many health devices sold today—light-therapy units, ultrasonic and laser-based home devices, air treatment appliances, battery-powered wearables—are electronics products first and enclosures second. Their bill of materials is dominated by PCBAs, power management, sensors, and custom modules, not by the injection-molded shell. A base whose comparative advantage is cheap assembly labor optimizes the least valuable part of that BOM. A base with electronics design depth and tooling under one roof optimizes the part that actually determines whether the device works, passes testing, and survives four years in a consumer’s bathroom.

None of this makes Taiwan the cheapest option on assembly labor. It makes Taiwan a credible answer when the four dimensions above outrank the unit-cost line—which, for regulated and quasi-regulated health devices, they usually do.

The migration playbook

Moving or adding a device production base is an engineering project, not a purchasing decision. Three workstreams determine whether it goes smoothly.

Tooling transfer. Existing molds either move or get rebuilt, and neither is automatic. Molds designed for one shop’s presses and process windows often need refurbishment or re-cutting to run elsewhere, and the receiving site has to re-validate the process rather than assume the old parameters carry over. Budget for a tool-transfer qualification, not a shipment.

Documentation rebuild. A device transfer is only as good as the package that travels with it: the device master record, drawings and revision history, bills of material, work instructions, inspection criteria, and test protocols. Gaps that were invisible while the original line ran on tribal knowledge surface immediately at a new site. A disciplined transfer treats documentation reconstruction as the first deliverable, before the first pilot run.

Dual sourcing. The lowest-risk path is rarely a hard cutover. Qualifying a second source and running both in parallel for a period lets you validate the new site against real output, keep supply continuous, and retain leverage—at the cost of carrying two qualifications for a while. For most brands adding a China+1 site, that transitional overlap is cheaper than a single-source gamble. The overlap also surfaces the differences that matter: two sites running the same drawings will produce measurably different parts, and the gap between them is exactly the process knowledge that never made it into the documentation. Running both long enough to reconcile that gap is how a China+1 site stops being a backup and becomes a genuine second source.

Sequenced together, these workstreams argue for choosing a base on qualification speed and engineering responsiveness rather than on the headline assembly rate. A site that shaves a few points off unit cost but adds months to tool transfer and documentation rebuild is, on a total-program basis, the more expensive choice.

Where Gooten fits

Gooten is a Taichung-based OEM/ODM manufacturer founded in 1996, with production, R&D, and quality assurance co-located at a single site in Daya. The company holds ISO 13485:2016 and ISO 9001:2015 certification and has compliance experience across CE, FCC, RoHS, and PSE, plus documentation and testing support for FDA submissions. To date it has shipped more than 1,000,000 units to customers in over 50 countries. You can review the full certification set on the quality certifications page.

The capabilities map to the four-dimension framework directly. In-house mechanical and electronic R&D, proprietary tooling, PCB/PCBA design and SMT, battery and power management, UV-C modules, 40 kHz ultrasonic transducers, and medical-grade laser modules mean design changes are handled locally rather than routed offshore. Work begins under NDA; engineers reply to customers directly; and programs run on dedicated assembly lines. The structured five-stage process—market positioning, R&D consulting, tooling and cost, custom packaging, and quality assurance across pre-production, in-process, and final inspection with third-party testing—is built to make a transfer auditable at each step.

The depth of the relationships is the more telling signal. Gooten’s longest active engagement has run more than 18 years across four product generations of a home-use device program—the kind of continuity that a documentation-heavy, tooling-intensive category rewards. For a fuller picture of how this maps to a China+1 device program, see the medical device contract manufacturer in Taiwan resource.

Next step

If you are scoping a second production base for a medical or health device, the productive first move is not a quote—it is a scoping conversation about your device’s tooling, documentation state, and qualification requirements. Start there, under NDA, with the engineers who would run the program. That conversation will tell you more about fit than any price sheet, and it is the honest way to find out whether Taiwan, and Gooten, belong on your China+1 shortlist.